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Abstract 52 
Given that the enhanced oxidative adaptations observed when training in carbohydrate (CHO) restricted states 53 
are potentially regulated through free fatty acid (FFA) mediated signalling and that leucine rich protein elevates 54 
muscle protein synthesis, the present study aimed to test the hypothesis that leucine enriched protein feeding 55 
enhances circulating leucine concentration but does not impair FFA availability nor whole body lipid oxidation 56 
during exercise. Nine males cycled for 2 h at 70% VO2peak when fasted (PLACEBO) or having consumed a 57 
whey protein solution (WHEY) or a leucine enriched whey protein gel (GEL), administered as 22 g 1 hour pre-58 
exercise, 11 g/h during and 22 g thirty minutes post-exercise.  Total leucine administration was 14.4 g and 6.3 in 59 
GEL and WHEY, respectively. Mean plasma leucine concentrations were elevated in GEL (P= 0.001) compared 60 
with WHEY and PLACEBO (375 ± 100, 272 ± 51, 146 ± 14 µmol.L-1 respectively). No differences (P= 0.153) 61 
in plasma FFA (WHEY 0.53 ± 0.30, GEL 0.45 ± 0.25, PLACEBO 0.65 ± 0.30, mmol.L -1) or whole body lipid 62 
oxidation during exercise (WHEY 0.37 ± 0.26, GEL 0.36 ± 0.24, PLACEBO 0.34 ± 0.24 g/min) were apparent 63 
between trials, despite elevated (P= 0.001) insulin in WHEY and GEL compared with PLACEBO (38 ± 16, 35 ± 64 
16, 22 ± 11 pmol.L-1 respectively).  We conclude that leucine enriched protein feeding does not impair FFA 65 
availability nor whole body lipid oxidation during exercise, thus having practical applications for athletes who 66 
deliberately train in CHO restricted states to promote skeletal muscle adaptations. 67 
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Introduction  77 
Traditional nutritional approaches for endurance training have typically promoted high CHO availability before, 78 
during and after training sessions in order to ensure high daily training intensities and volumes as well as 79 
promoting recovery (Cermak and Van Loon, 2013; Hawley et al. 1997). However, during the last decade, we 80 
and others have consistently observed a potent effect of reduced CHO availability (i.e. fasted and/or glycogen 81 
depleted training) in modulating training-induced adaptations in skeletal muscle (Hawley and Morton, 2014).  82 
For example, reducing endogenous and/or exogenous CHO availability during short-term (e.g. 3-10 week) 83 
endurance training increases mitochondrial enzyme activity and protein content (Morton et al., 2009; Yeo et al., 84 
2008; Van Proeyen et al., 2011), increases both whole body (Yeo et al., 2008) and intramuscular lipid oxidation 85 
(Hulston et al., 2010), and in some instances, improves exercise capacity (Hansen et al., 2005).  These data have 86 
therefore led to the innovative “train-low, compete-high” model surmising that athletes deliberately complete a 87 
portion of their training programme with reduced CHO availability so as to augment training adaptation but yet 88 
always ensure high CHO availability prior to and during competition in an attempt to promote maximal 89 
performance (Burke, 2010). The augmented training response observed with training-low strategies are 90 
currently thought to be regulated via the enhanced activation of upstream cell signalling kinases including both 91 
AMPK (Yeo et al. 2010) and p38MAPK (Cochran et al. 2010) that ultimately converge on the downstream 92 
regulation of key transcription factors and co-activators such as PGC-1α (Psilander et al. 2013), p53 (Bartlett et 93 
al. 2013) and PPARδ (Philp et al. 2013). In this way, training with low CHO availability thereby leads to a co-94 
ordinated upregulation of both the nuclear and mitochondrial genomes. 95 
Despite the emergence of the train-low paradigm, its practical application in athletic populations is not without 96 
limitations, most notably a potential reduction in absolute training intensities (Yeo et al. 2008) as well as 97 
increased skeletal muscle protein oxidation and breakdown (Lemon and Mullin, 1980; Howarth et al. 2010).  An 98 
obvious solution to compensate for the latter is to consume high quality protein in close proximity to the 99 
exercise stimulus given that protein provision before (Coffey et al. 2011), during (Hulston et al. 2011) and after 100 
exercise (Breen et al. 2011; Howarth et al. 2010) is facilitative of a positive net protein balance. In this regard, 101 
Pasiakos et al. (2011) also observed that enhanced concentration of leucine (3.5 g in 10 g EAA) in an essential 102 
amino acid mixture consumed during two hours of endurance exercise significantly enhanced post-exercise 103 
muscle protein synthesis rates when compared with the same total intake of essential amino acids containing 104 
reduced leucine concentration (1.87 g in 10 g EAA).  We also observed that consuming protein before, during 105 
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and after acute exercise undertaken in a glycogen depleted state did not impair the activation of the AMPK- 106 
PGC-1α pathway and positively affected molecular regulators of protein synthesis (e.g. eEF2 phosphorylation 107 
status), thus demonstrating that high amino acid availability still permits activation of key cell signalling 108 
cascades thought to regulate the training-low response (Taylor et al. 2013). When taken together, such data 109 
suggest that reduced CHO but high protein availability (especially leucine rich protein) may therefore be a 110 
strategic approach to stimulate training-induced adaptations of skeletal muscle.  111 
It is noteworthy, however, that the provision of high protein availability could hinder additional pathways that 112 
may be involved in regulation of the training response associated with training-low. Indeed, we observed that 113 
the elevated insulin induced by amino acid ingestion (albeit administered as a casein hydrolysate solution) 114 
attenuated circulating free fatty acid (FFA) availability and whole body rates of lipid oxidation (Taylor et al. 115 
2013).  This effect may be problematic given that FFA may also act as signalling intermediates involved in 116 
regulating training adaptation in addition to providing substrate for oxidation (Zbinden et al. 2014; Philp et al. 117 
2013; Fyffe, et al. 2006). Any feeding strategy intended to achieve high protein availability (in an attempt to 118 
reduce protein breakdown and promote protein synthesis) during acute train-low sessions should therefore be 119 
simultaneously administered with the goal of minimising reductions in lipolysis such that FFA mediated cell 120 
signalling can still occur. 121 
Accordingly, the aim of the current study was to therefore test the hypothesis that leucine enriched protein 122 
feeding enhances circulating leucine availability but does not impair FFA availability and lipid oxidation during 123 
exercise. To this end, we utilised two protein feeding strategies consisting of a traditional whey protein solution 124 
but also a novel leucine enriched protein gel.  The use of the latter is considered particularly advantageous for 125 
endurance athletes given that gels are a highly practical approach to feeding when in locomotion (Pfeiffer et al., 126 
2010, 2012; Lee et al. 2014). When taken together, it is hoped that our data will be of immediate practical 127 
application for those athletes who deliberately train in CHO restricted states in order to promote skeletal muscle 128 
adaptations that are reflective of both mitochondrial and myofibrillar protein synthesis.  129 
 130 
 131 
 132 
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Methodology   133 
Subjects: Nine males (age 29 ± 4 years, height 179.7 ± 2.9 cm and body mass 79.4 ± 3.3 kg) volunteered to 134 
participate in the study after providing informed written consent. Subjects were recreational and competitive 135 
cyclists and tri-athletes who trained between 3 – 7 hours per week and had been cycling regularly for > 1 year. 136 
Mean VO2peak and peak power output (PPO) for the cohort was 53.0 ± 2.1 ml.kg-1.min-1 and 334 ± 13 W 137 
respectively. None of the subjects had a history of neurological disease or skeletal muscle abnormality and none 138 
were under pharmacological intervention during the course of the study. Subjects were asked to maintain 139 
habitual activity levels during the course of the study. The study was approved by the Research Ethics 140 
Committee of Liverpool John Moores University.  141 
Overview of Experimental Design: In a repeated measures counter-balanced design (using a Latin Squares 142 
approach) and after having previously completed an assessment of VO2peak and PPO, subjects reported to the 143 
laboratory on the morning of the experimental trial (following an overnight fast) on 3 occasions separated 5-7 144 
days. To determine the sequence of testing (i.e. the order of which subjects were tested from 1-9), subjects were 145 
drawn from a random number generator.  Subjects consumed a standardised diet (5 g.kg-1 CHO, 2 g.kg-1 Protein, 146 
1 g.kg-1 Fat) and refrained from exercise for the 48 h prior to all of the testing procedures. With the exception of 147 
the breakfast and pre-bedtime snack (both of which were made by the subject themselves and consumed in their 148 
own home after appropriate dietary instruction), all food was provided in pre-packaged containers and 149 
consumed on the university premises in view of author one so as to verify compliance. On arrival at the 150 
laboratory on the morning of the experimental trial, subjects consumed a protein (in the form of whey or gel) or 151 
placebo supplement 1 h prior to commencing 2 h of cycling at 60% PPO (~ 70% VO2peak), at 30 min intervals 152 
during exercise and a final dose at 30 minutes post-exercise. Venous blood samples were taken at regular 153 
intervals prior to, during and after exercise.  Measurements of heart rate, substrate oxidation and subjective 154 
ratings of perceived exertion, enjoyment and gastrointestinal discomfort were obtained during exercise.  155 
Assessment of maximal oxygen uptake: Peak oxygen consumption (VO2peak) and peak aerobic power (PPO) 156 
were determined during an incremental cycle test performed on an electromagnetically braked cycle ergometer 157 
(SRM, Julich, Germany). The subjects completed a 10 min warm up at 100 W and self-selected cadence, before 158 
commencing the test which consisted of 2 min stages with 30 W increments in power until volitional exhaustion. 159 
Breath-by-breath measurements were obtained throughout exercise using a CPX Ultima series online gas 160 
analysis system (Medgraphics, Minnesota, US). VO2peak was stated as being achieved by the following end-point 161 
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criteria: 1) heart rate within 10 beats.min-1 of age-predicted maximum, 2) respiratory exchange ratio > 1.1, and 3) 162 
plateau of oxygen consumption despite increased workload. Peak aerobic power was taken as the final stage 163 
completed during the incremental test. 164 
Experimental protocol: Participants arrived at the laboratory in the morning of the trial (08:00) having 165 
followed a prescribed diet for two days prior and following an overnight fast. After obtaining measures of nude 166 
body mass, an indwelling cannula (Safety Lock 22G, BD Biosciences, West Sussex UK) was inserted into the 167 
anticubital vein in the anterior crease of the forearm and a resting blood sample drawn.  After the resting blood 168 
sample was taken, the cannula was flushed with ~ 5 ml of sterile saline (Kays Medical supplies. Liverpool UK) 169 
to keep the cannula patent and sterile, this procedure was repeated after each subsequent blood draw. Having 170 
obtained a resting sample, subjects’ ingested ether a non-caloric placebo gel and 500 ml of water (PLACEBO), a 171 
leucine enriched protein gel that is not currently commercially available (GEL) providing 22 g protein + 2.4 g 172 
leucine (total leucine of 4.8 g) with 500 ml of water, or 22 g of commercially available whey protein (total 173 
leucine of 2.1 g; REGO Protein, Science in Sport, UK) mixed in 500 ml water (WHEY) and then rested in the 174 
laboratory for 60 min prior to the start of exercise. The nutritional compositions of the protein supplements are 175 
shown in Table 1.  Both the protein gel and placebo gel (containing Water, Gellan Gum, Sodium Citrate, 176 
Sodium Benzoate, Potassium Sorbate, Sodium Chloride, Xanthan Gum, Acesulfame K, Ascorbic Acid and 177 
Citric Acid) are not currently commercially available and were manufactured flavour matched in-house in an 178 
Informed Sport accredited laboratory (Science in Sport, SiS, Nelson, UK).  On the basis that caffeine can 179 
partially restore training intensity when in glycogen depleted states (Lane et al. 2013) and also that beta-hydroxy 180 
beta-methylbutyrate (HMB) can reduce muscle protein breakdown (Wilkinson et al. 2013), we also chose to 181 
fortify our GEL with additional caffeine (100 mg per 22 g of protein) and HMB (1 g per 22 g of protein).  Blood 182 
samples were obtained repeatedly at 20 min intervals during the pre-exercise period and immediately before 183 
exercise commenced. Subjects then cycled for 120 min at 60% PPO (~70% VO2peak) on a fully adjustable 184 
electromagnetically braked cycle ergometer (SRM, Julich, Germany). Each subject used their own pedals, cleats 185 
and shoes during each trial.  During exercise, feeding of 11 g whey protein with 250 ml water occurred at 30 186 
min, 5.5 g at 60 and 90 min in 125 ml water, or a volume matched placebo or protein gel and water. Blood 187 
samples were taken every 20 minutes during exercise and at termination. Substrate oxidation (g.min-1) was 188 
determined during exercise using CPX Ultima series online gas analysis system (Medgraphics, Minnesota, US) 189 
using equations of Jeukendrup and Wallis (2005). Ratings of perceived exertion (RPE) (Borg 1970), 190 
gastrointestinal discomfort (GI) (Pfieffer, et al. 2012) and heart rate (Polar Kempele 610i, Finland) were 191 
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recorded every 15 min during exercise. Upon completion of exercise, subjects dismounted from the ergometer, 192 
towel dried and nude mass was recorded. Thirty minutes after exercise, subjects consumed a further 22 g of 193 
protein or placebo with 500 ml water in the form of WHEY or GEL and and two more blood samples were 194 
taken at 1 h and 2 h after completion of exercise. Laboratory conditions remained constant across all trials (19 - 195 
21 ̊C, 40 – 50% humidity). In this way, subjects consumed a total of 66 g protein during the protein trials (i.e. 22 196 
g before, 22 g during and 22 g after exercise) in the form of whey protein (total leucine intake of 6.3 g) or a 197 
leucine enriched protein gel (total leucine intake of 14.4 g). Upon exercise completion, subjects also rated their 198 
perceived ratings of enjoyment as quantified by the Physical Activity Enjoyment Scale (Kenzierski and DiCarlo, 199 
1991). 200 
 201 
Blood analysis: Blood samples were collected in vacutainers containing K2 EDTA, lithium heparin or serum 202 
separation tubes, and stored on ice or at room temperature until centrifugation at 1500 g for 15 min at 4 ̊C. 203 
Serum and plasma were aliquoted and stored at -80 ̊C until analysis. Plasma glucose, lactate, FFA and glycerol 204 
were analysed using the Randox Daytona spectrophotometer with commercially available kits (Randox, Ireland), 205 
as per the manufacturer’s instructions. Serum insulin concentrations were analysed using commercially 206 
available ELISA (Cobas, Roche Diagnostics, USA) as per the manufacturer’s instructions. Plasma amino acids 207 
were quantified as their tert-butyldimethylsilyl (t-BDMS) derivatives after the addition of suitable internal 208 
standards by Gas Chromatography-Mass Spectrometry: briefly, 200 µl of plasma was deproteinized with 1 ml of 209 
100% ethanol, the supernatant dried under nitrogen at 90oC, re-dissolved in 500 µl 0.5 M HCl, extracted with 210 
2ml ethyl acetate (to remove lipid fraction), and the aqueous layer was then dried and derivatized (with 100 µl 211 
Acetonitrile and 100 µl MTBSTFA) at 90oC for 90 min.  The t-BDMS BCAA derivatives were separated on 212 
RTX5-ms (15m x 0.25 id, 0.25 µ film thickness) capillary column, initial column temp 70oC, then ramped at 213 
12oC/min to 280oC, injector temperature was 240oC, Helium carrier gas was 1.2 ml/min. Selected ion 214 
monitoring of the (M-57) fragment was performed for each amino analysed, and the area under the peak 215 
determined relative to the mass isotopomer of the stable isotopically labelled internal standard used for each 216 
amino acid e.g. we monitored m/z 302 for Val and Leu and the isotopomer 303 (for 13C Valine) and 304 (for 217 
1,2 13C2 Leucine).  218 
 Statistical analysis. Statistical analysis was conducted using the Statistical Package for the Social Sciences 219 
software program (SPSS, version 18). Changes in physiological and metabolic responses (i.e. physiological 220 
variables, amino acids, metabolites and substrate oxidation rates) were analysed using a two-way repeated 221 
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measures general linear model (GLM) where the within factors were time and condition. Additionally, area 222 
under the curve (AUC) for metabolites, amino acids and insulin were also calculated (using Graph Pad Prism, 223 
version 6) and differences between conditions were assessed using a one-way repeated measures GLM. A 224 
comparison of subjects’ perceived rating of enjoyment during exercise was also analysed according to a one-225 
way repeated measures GLM where the. Where a significant main effect was observed, pairwise comparisons 226 
were analysed according to Bonferoni post-hoc tests in order to locate specific differences. Statistical 227 
significance was set at P < 0.05 and all data in text, figures, and tables are presented as means ± SEM.   228 
 229 
Results 230 
Physiological and perceptual responses during exercise 231 
A comparison of subjects’ physiological and perceptual responses during the exercise protocol is shown in 232 
Table 2. Heart rate (P<0.01), lipid oxidation (P<0.01) and RPE (P<0.01) all displayed progressive increases 233 
during exercise, whereas CHO oxidation exhibited a significant decline (P<0.01). In contrast, GI discomfort 234 
displayed no change during exercise (P=0.14). However, there was no difference in heart rate (P=0.84), oxygen 235 
uptake (P=0.67), CHO oxidation (P=0.97), lipid oxidation (P=0.90), RPE (P=0.11) and GI discomfort (P=0.19) 236 
between the PLACEBO, GEL and WHEY trials. Subjects also reported a tendency for a higher rating of 237 
perceived enjoyment (P=0.073) in the GEL (89 ± 5 AU) versus the WHEY (84 ± 5 AU) and PLACEBO (79 ± 5 238 
AU) trials. 239 
Metabolic responses and substrate oxidation during exercise 240 
Serum insulin significantly increased in the pre-exercise period and also showed significant declines during 241 
exercise (P<0.01) in both the WHEY and GEL trials (see Figure 1). Accordingly, insulin displayed significant 242 
differences between conditions (P<0.01) where both WHEY (P<0.01) and GEL (P=0.01) were significantly 243 
higher than PLACEBO (see Figure 1) though no differences were apparent between the WHEY and GEL trials 244 
(P=1.0). Total AUC for insulin also displayed differences (P<0.01) between conditions such that both WHEY 245 
and GEL were different from PLACEBO (P<0.01 and =0.01, respectively) but no differences occurred between 246 
WHEY and GEL (P=1.0) 247 
  Exercise induced significant increases in plasma NEFA (P<0.01), glycerol (P<0.01) and lactate 248 
(P<0.01) whereas glucose displayed no significant (P=0.09) change (see Figure 2 A, C, E and F, respectively).  249 
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Despite significant changes in insulin in the protein fed trials, plasma NEFA (P=0.12), glycerol (P=0.42), 250 
glucose (P=0.19) and lactate (P=0.06) were not different between the PLACEBO, WHEY and GEL trials at rest 251 
or during exercise. Accordingly, total AUC for NEFA (P=0.09), glycerol (P=0.38), glucose (P=0.1) and lactate 252 
(P=0.07) also displayed no differences between treatments.  253 
 254 
Plasma amino acid responses  255 
Plasma leucine, BCAAs and EAAs are displayed in Figure 3 A, C and E, respectively. Feeding-induced 256 
increases in plasma leucine (P<0.01) were significantly different between conditions (P<0.01) such that a 257 
significant interaction effect was observed (P=0.02). Specifically, plasma leucine was significantly greater in 258 
GEL versus both WHEY (P<0.01) and PLACEBO (P<0.01). As such, total AUC for leucine was also different 259 
between treatments with differences evident across all pair-wise comparisons (all P<0.01) (see Figure 3 B). 260 
Similar to leucine, feeding also induced a significant increase (both P<0.01) in plasma BCAAs and 261 
EAAs for both WHEY and GEL where both a significant effect of condition (both P<0.01) and interaction 262 
(P<0.01 and P=0.04, respectively) was observed. However, pairwise comparisons revealed there to be no 263 
differences in total BCAAs and EAAs between GEL and WHEY (P=1.0 and 0.6, respectively) though both were 264 
different from PLACEBO (P<0.01). In accordance, although total AUC for BCAAs and EAAs displayed 265 
significant main effects between treatments (both P<0.01), significant pairwise effects (all P<0.01) were only 266 
apparent when comparing GEL and WHEY from PLACEBO (see Figure 3 D and F). 267 
  268 
Discussion 269 
The aim of the present study was to test the hypothesis that leucine enriched protein feeding enhances 270 
circulating leucine availability but does not impair FFA availability and lipid oxidation during exercise. To this 271 
end, we utilised two protein feeding strategies consisting of a traditional whey protein solution but also a novel 272 
leucine enriched protein gel.  We provide novel data by demonstrating that provision of protein (in either of the 273 
aforementioned forms) before, during and after two hours of endurance exercise undertaken in the absence of 274 
CHO feeding pre- and during exercise does not impair FFA availability or lipid oxidation. Given that the 275 
enhanced training response observed when training in CHO restricted states is potentially regulated through 276 
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FFA mediated signalling and also that leucine enriched protein elevates muscle protein synthesis, we therefore 277 
consider our data to have practical implications (i.e. feeding strategies) for those athletes who deliberately train 278 
in CHO restricted states in order to enhance skeletal muscle adaptations to endurance training.  279 
Despite the apparent advantage to carefully scheduling periods of fasted (Van Proeyen et al. 2011) and/or 280 
glycogen depleted endurance training (Yeo et al. 2008; Morton et al. 2009), such approaches may be limited in 281 
that skeletal muscle protein oxidation and breakdown is increased (Lemon and Mullin, 1980; Howarth et al. 282 
2009) and hence, net protein balance becomes negative if amino acids are also not ingested (Hulston et al. 2011).   283 
If performed chronically (especially in the presence of reduced daily caloric intake), this approach could 284 
therefore lead to a loss of skeletal muscle mass (Cabone et al. 2013; Mettler et al. 2010; Pasiakos et al. 2013) 285 
and potentially, a de-training effect (Breen et al. 2011). To this end, we recently demonstrated that consuming a 286 
casein hydrolysate solution before, during and after glycogen depleted exercise does not impair activation of 287 
mitochondrial related signalling pathways (e.g. AMPK- PGC-1α) as well as positively affecting molecular 288 
regulators of protein synthesis (e.g. eEF2 phosphorylation status) (Taylor et al. 2013).  As such, many elite 289 
endurance cyclists now perform prolonged morning rides in CHO restricted states but with protein rich 290 
breakfasts and additional protein during exercise (typically in the form of whey / casein drinks) in a deliberate 291 
attempt to promote oxidative adaptations of skeletal muscle (Walsh, 2014).   292 
In terms of modulating protein synthesis, however, current evidence also suggests that both rapidly digestible 293 
but leucine rich proteins are the optimal protein source. For example, Pasiakos et al. (2011) observed that 294 
enhanced concentration of leucine (3.5 g in 10 g EAA) in an essential amino acid mixture consumed during two 295 
hours of endurance exercise significantly enhanced post-exercise muscle protein synthesis rates when compared 296 
with the same total intake of essential amino acids but containing reduced leucine concentration (1.87 g in 10 g 297 
EAA).  Furthermore, Churchward-Venne et al. (2014) demonstrated comparable post-exercise myofibrillar 298 
synthesis rates (albeit from a resistance exercise stimulus) from mixed macronutrient drinks containing 25 g 299 
whey versus a bolus of 6.25 g whey supplemented with 5 g leucine. Such observations therefore formed the 300 
underlying rationale for the present study in terms of studying whey protein (naturally high in leucine) but also, 301 
a novel leucine enriched protein gel. Total leucine administration during the data collection period (i.e. 5 hours) 302 
was 14.4 and 6.3 g in WHEY and GEL, respectively.  Accordingly, mean plasma leucine levels were higher in 303 
GEL versus WHEY and in both feeding strategies, plasma leucinemia increased to levels that would be expected 304 
to promote post-exercise muscle protein synthesis (Breen et al. 2011; Pasiakos et al. 2011).  Unfortunately, 305 
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direct estimates of muscle protein synthesis (and related molecular regulators) were not obtained in the present 306 
study nor did we quantify rates of leucine oxidation. Future studies would therefore benefit from direct measures 307 
of both mixed muscle protein synthesis (and in sub-cellular fractions) as well as leucine oxidation, both 308 
achieved via the inclusion of muscle biopsies and stable isotope methodology.  309 
Although we readily acknowledge that the total leucine delivery in both trials may appear as excessive in terms 310 
of that required to facilitate maximal protein synthesis as well as likely resulting in elevated leucine oxidation 311 
(Bowtell et al. 1998), we deliberately chose this dosing strategy for a number of practical reasons. Firstly, given 312 
that exercising in CHO restricted states augments leucine oxidation (Lemon and Mullin, 1980; Wagenmakers et 313 
al. 1991; Howarth et al. 2009), it was our deliberate aim to administer higher exogenous leucine so as to deliver 314 
both substrate to promote muscle protein synthesis (Breen et al. 2011; Pasiakos et al. 2011; Churchward-Venne 315 
et al. 2013) but yet, also compensate for the higher levels of endogenous leucine oxidation (Lemon and Mullin, 316 
1980; Wagenmakers et al. 1991; Howarth et al. 2009).  Second, unpublished observations by the corresponding 317 
author on elite professional cyclists indicated that this is the type of protein feeding strategy actually adopted 318 
during morning training rides that are deliberately undertaken in the absence of CHO intake before and during 319 
exercise.  As such, our initial aim was to replicate these “real world” strategies and determine if such doses of 320 
protein actually impairs FFA availability and lipid oxidation.  Finally, given that many elite cyclists are 321 
potentially in daily energy deficits (Vogt et al. 2005) with low energy availability (Loucks et al. 2011), and also 322 
that 2-3 x RDA for daily protein is required to maintain lean mass during energy restriction (Pasiakos et al. 323 
2013), we therefore considered this feeding strategy to be in accordance with daily protein intakes for both 324 
quantity and frequency (Areta et al. 2013).  For example, over the 5 h data collection period (i.e. 8 am to 1 pm), 325 
the present subjects (ranging from 67-86 kg) consumed 66 g protein and hence for the daily target to be 326 
achieved (i.e. approximately 160-200 g), our approach is therefore in accordance with a feeding strategy where 327 
subsequent 30 g doses could be consumed at 3 h intervals (e.g. 2, 5, 8 and 11 pm if required). 328 
In terms of modulating the train-low response, the important aspect of the present paper is that neither the whey 329 
protein solution nor the leucine enriched protein gel attenuated circulating FFA availability or whole body rates 330 
of lipid oxidation during exercise, despite elevated serum insulin levels in the pre-exercise period. This finding 331 
is especially relevant considering that the enhanced training response observed when training with low CHO 332 
availability (particularly the elevated capacity for lipid oxidation during customary exercise) is likely regulated, 333 
in part, through FFA mediated signalling.  Indeed, the exercise-induced increase in p38MAPK activity is 334 
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blunted by pharmacological reduction of circulating FFA availability  (Zbinden et al. 2014).  Furthermore, 335 
exercise undertaken in a glycogen-depleted state increases PPARδ binding to the CPT1 promoter (Philp et al. 336 
2013), the latter considered as a rate limiting enzyme for long chain fatty acid oxidation.  The observation of no 337 
apparent reduction in lipolysis with protein feeding in the present study disagrees with previous observations 338 
from our laboratory where we demonstrated that a casein hydrolysate solution (administered as 20 g 45 min pre-339 
exercise, 10 g during exercise and 20 g post-exercise) attenuated plasma FFA availability and whole body rates 340 
of lipid oxidation during exercise.  Such discrepancies may be due in part to differences in timing of pre-341 
exercise feeding (i.e. 60 versus 45 minutes before exercise) as well as type of protein consumed (i.e. casein 342 
hydrolysate versus predominantly whey isolate proteins). The latter point is particularly relevant given that 343 
hydrolysate proteins induce greater insulin responses compared with isolated protein sources (Tang et al. 2009; 344 
Pennings et al. 2011). As such, the effects of protein ingestion on metabolic responses during exercise are likely 345 
dependent upon the interplay of a number of important factors including type and timing of protein ingestion. 346 
Such factors should therefore be taken into consideration when designing real world feeding strategies. 347 
To achieve our delivery for the leucine enriched protein trial, we chose to develop a novel protein based gel. 348 
Indeed, considering that leucine is often not readily soluble in water, we reasoned that a gel format provided a 349 
more convenient approach for which to deliver a leucine enriched protein source. Moreover, gels are a highly 350 
practical approach to carrying fuel and feeding whilst in locomotion as opposed to conventional approaches of 351 
fluid delivery (Pfeiffer et al., 2010; Lee et al. 2014). Accordingly, gels are a highly utilised form of supplement 352 
by endurance athletes (Pfeiffer et al., 2012).  On the basis that caffeine can partially restore training intensity 353 
when in glycogen depleted states (Lane et al. 2013) and also that beta-hydroxy beta-methylbutyrate (HMB) can 354 
reduce muscle protein breakdown (Wilkinson et al. 2013), we also chose to fortify our GEL with additional 355 
caffeine (100 mg per 22 g of protein) and HMB (1 g per 22 g of protein).  Although we did not measure 356 
parameters related to these products given that our exercise protocol was clamped (i.e. 2 h fixed intensity of 70% 357 
VO2peak) and no indices of protein breakdown were obtained, our observations of no differences in 358 
gastrointestinal discomfort between trials supports the notion that multiple ingredients in the gel format were 359 
well tolerated. Interestingly, subjects’ ratings of perceived enjoyment (as quantified by the Physical Activity 360 
Enjoyment Scale) also tended to be higher in GEL (90 ± 5) versus both WHEY (84 ± 5) and PLACEBO (79 ± 361 
5). Given that this scale takes into account subjective measurements of mood status related to vigor and arousal, 362 
this observation maybe related to the higher plasma concentrations of leucine observed in the GEL trial and is 363 
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accordance with the hypothesis that elevated BCAAs (especially in conditions of low CHO availability) may 364 
alleviate symptoms of central fatigue (Blomstrand et al., 2005; Blomstrand, 2006). 365 
In summary, we provide novel data by demonstrating that neither a whey protein solution nor a leucine enriched 366 
protein gel impairs circulating FFA availability or rates of whole body lipid oxidation during two hours of 367 
endurance exercise undertaken in a CHO restricted state.  Given that the augmented training response observed 368 
when training with reduced CHO availability (i.e. absence of CHO provision before/during exercise and/or 369 
glycogen depleted conditions) is potentially regulated through FFA mediated signalling and also that leucine 370 
rich protein elevates muscle protein synthesis, we consider our data to have practical implications for those 371 
athletes who deliberately train in CHO restricted states in order to enhance skeletal muscle adaptations to 372 
endurance training (as reflective of both mitochondrial and myofibrillar protein synthesis).  Further studies are 373 
now required to examine both the acute (e.g. cell signalling, gene expression responses and direct measures of 374 
protein turnover) and chronic effects (e.g. mitochondrial adaptations) of reduced CHO but high protein 375 
availability on skeletal muscle adaptation to endurance training as well as potential impact on measures of 376 
exercise performance.  377 
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 513 
TABLE 1 – Overview of the nutritional compositions of the GEL and WHEY products 514 
(protein in both products was from whey isolate sources).  515 
 516 
TABLE 2 – Physiological and perceptual responses during exercise. * denotes significant 517 
difference from 30 min, P<0.05. 518 
 519 
FIGURE 1 – Serum insulin concentrations before, during and after exercise. Total area under 520 
the curve for insulin is also shown inset. Shaded area represents the exercise bout. Downward 521 
arrows denote timing of treatment ingestion. * denotes significant difference from baseline 522 
values i.e. minute 0, P<0.05. a denotes significant difference from PLACEBO, P<0.05. 523 
 524 
FIGURE 2 – Plasma (A) NEFA, (C) glycerol, (E) glucose and (G) lactate before, during and 525 
after exercise. Shaded area represents the exercise bout. Downward arrows denote timing of 526 
treatment ingestion. Total area under the curve (AUC) for NEFA (B), glycerol (D), glucose 527 
(F) and lactate (H) are also shown in the right hand panels. * denotes significant difference 528 
from baseline values i.e. minute 0, P<0.05. 529 
 530 
FIGURE 3 – Plasma (A) leucine, (C) BCAAs, and (E) EAAs before, during and after 531 
exercise. Shaded area represents the exercise bout. Downward arrows denote timing of 532 
treatment ingestion. * denotes significant difference from baseline values i.e. minute 0, 533 
P<0.05. Total area under the curve (AUC) for leucine (B), BCAAs (D) and EAAs (F) are also 534 
shown in the right hand panels. a denotes significant difference from PLACEBO, P<0.05. b 535 
denotes significant difference from WHEY, P<0.05.  536 
 537 
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 545 
 546 
TABLE 1 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
 566 
 567 
 568 
 569 
 570 
 571 
 
 
GEL 
 
WHEY 
 
Total Protein (g) 22.0 22.0 
Additional Leucine (g) 2.4 0.0 
Total Leucine (g) 4.8 2.1 
Total BCAA (g) 7.5 4.9 
Total EAA (g) 13.1 9.3 
Caffeine  (mg) 100.0 0.0 
HMB (g) 1.0 0.0 
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 572 
 573 
TABLE 2 574 
         Time (min)   
 
 
30 60 90 120 
CHO Oxidation (g/min) 
    Gel 3.14 ± 0.18 2.70 ± 0.23* 2.25 ± 0.15*  1.98 ± 0.15* 
Placebo 3.13 ± 0.19 2.61 ± 0.18* 2.38 ± 0.15* 2.20 ± 0.13* 
Whey 3.13 ± 0.24 2.64 ± 0.22* 2.24 ± 0.17* 1.97 ± 0.18* 
     Lipid Oxidation (g/min) 
    Gel 0.12 ± 0.08 0.31 ± 0.11* 0.51 ± 0.06* 0.63 ± 0.05* 
Placebo 0.05 ± 0.07 0.34 ± 0.08* 0.47 ± 0.07* 0.61 ± 0.07* 
Whey 0.11 ± 0.09 0.40 ± 0.08* 0.47 ± 0.07* 0.60 ± 0.07* 
     HR  (b/min) 
    Gel 149 ± 4 154 ± 3 158 ± 4* 164 ± 4* 
Placebo 148 ± 3 153 ± 3 157 ± 4* 164 ± 4* 
Whey 152 ± 5 156 ± 3 157 ± 4* 163 ± 3* 
     VO2 (%max) 
    Gel 67± 2 68 ± 2 68 ± 2 67 ± 3 
Placebo 67 ± 1 67± 1 68± 2 70 ± 2 
Whey 66 ± 2 69 ± 1  67 ± 2 68 ± 3 
     RPE (AU) 
    Gel 11 ± 1 13 ± 1* 13 ± 1* 14 ± 1* 
Placebo 12 ± 1 14 ± 1* 15 ± 1* 16 ± 1* 
Whey 12 ± 1 14 ± 1* 14 ± 1* 15 ± 1* 
     GI (AU) 
    Gel 10 ± 1 10 ± 1 10 ± 1 10 ± 1 
Placebo 9 ± 1 10 ± 1 10 ± 1 9 ± 1 
Whey 10 ± 1 11 ± 1 11 ± 1 10 ± 1 
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